Abstract: The present invention relates to the technical field of power electronics converters and discloses a grid-forming energy storage converter on/off-grid switching control method and system, where the method includes the following steps: S1: using a single-loop power control strategy in an off-grid state when an on-grid relay of target energy storage drops out; S2: using a parallel virtual impedance loop-based power control strategy in a transient on-grid state when the on-grid relay of target energy storage pulls in; and S3: using a cascaded dual-loop power control strategy with a virtual admittance voltage loop and an inner current loop when a stable on-grid state is established. The present invention solves the problems of large current impact and unstable switching process state in the existing working strategy for on/off-grid switching in the prior art.

Abstract: A method for selection of a calibration set and a validation set based on spectral similarity and modeling. The method includes: performing NIR spectrometry on original samples to obtain a spectral matrix of the original samples; randomly selecting m samples as an independent test set; calculating spectral similarity between each of the samples in the independent test set and each of the remaining samples in the original samples respectively to obtain g samples having the highest similarity to be written into the validation set; and calculating spectral similarity between each of the samples in the validation set and each of the remaining samples in the original samples respectively to obtain n samples having the highest similarity to be written into the calibration set. Based on the validation set and the calibration set selected through the method, an obtained model can predict unknown samples more accurately.

Abstract: A JAK kinase inhibitor and use thereof. The JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof. Further, the use of the compound of formula I in preparation of drugs for preventing or treating JAK kinase-related diseases, especially in preparation of drugs for preventing and/or treating diseases involving cartilage degradation and bone and/or joint degradation, conditions involving inflammation or immune response, endotoxin-driven disease states, cancer, and organ transplantation rejection.

Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.

Abstract: A method for selection of a calibration set and a validation set based on spectral similarity and modeling. The method includes: performing NIR spectrometry on original samples to obtain a spectral matrix of the original samples; randomly selecting m samples as an independent test set; calculating spectral similarity between each of the samples in the independent test set and each of the remaining samples in the original samples respectively to obtain g samples having the highest similarity to be written into the validation set; and calculating spectral similarity between each of the samples in the validation set and each of the remaining samples in the original samples respectively to obtain n samples having the highest similarity to be written into the calibration set. Based on the validation set and the calibration set selected through the method, an obtained model can predict unknown samples more accurately.

Abstract: The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.

Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.

Abstract: The application discloses five polymorph forms B, P, F, J, O of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxyphenyl)methyl)phenyl)(4-methylpiperidine-1-yl)methanone dihydrochloride, preparation methods thereof and application thereof in the manufacture of a medicament for preventing or treating a mood disorder or a disease related to a ? opioid receptor.

Abstract: The application discloses five polymorph forms B, P, F, J, O of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxyphenyl)methyl)phenyl)(4-methylpiperidine-1-yl)methanone dihydrochloride, preparation methods thereof and application thereof in the manufacture of a medicament for preventing or treating a mood disorder or a disease related to a ? opioid receptor.

Abstract: The invention relates to a 4-substituted pyrrolo[2,3-d]pyrimidine compound and the use thereof in preparing medications for treating JAK-targeted diseases such as rheumatoid, immune system diseases, and tumor. The 4-substituted pyrrolo[2,3-d]pyrimidine compound of the invention is as shown in chemical formula I. The activity experimental results of the invention show that the new compound has obvious effect and activity in inhibition of Janus kinases, JAK-STAT, cell proliferation of human lymphocytoma, and rheumatoid arthritis.

Abstract: The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.

Abstract: The invention relates to a 4-substituted pyrrolo[2,3-d]pyrimidine compound and the use thereof in preparing medications for treating JAK-targeted diseases such as rheumatoid, immune system diseases, and tumor. The 4-substituted pyrrolo[2,3-d]pyrimidine compound of the invention is as shown in chemical formula I. The activity experimental results of the invention show that the new compound has obvious effect and activity in inhibition of Janus kinases, JAK-STAT, cell proliferation of human lymphocytoma, and rheumatoid arthritis.

Abstract: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

Abstract: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

Abstract: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Abstract: The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

Abstract: The present invention relates to compounds of Formula (I): (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

Abstract: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.